Search

Displaying results 3191 - 3200 of 4859 in total
  1. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    [A233265] It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide.

  2. Drug

    Mubodina

    go.drugbank.com/drugs/DB17616
    Experimental

    It is a recombinant human minibody directed against complement component C5. … It was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome.

  3. Drug

    2,4-Dinitrophenol

    go.drugbank.com/drugs/DB04528
    Experimental

    It is also used as a metabolic stimulant. (Stedman, 26th ed) … A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation.

  4. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.

  5. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    It is produced by recombinant DNA technology using a mammalian cell expression system. … [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_.

  6. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    It is implanted in patients undergoing bone surgeries or those with fractures. … In 2004, it was approved by the FDA and is marketed as Infuse. In Infuse, rhBMP is a disulfide-linked dimeric protein molecule with two major subunit species of 114 and 131 amino acids.

  7. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. … [L12624] It is additionally approved in Canada under the same name (Imfinzi) for similar indications, as well as the treatment of patients with locally advanced or metastatic urothelial carcinoma.

  8. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [L39544] It was fully approved by the FDA on May 25, 2023. … [L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital.

  9. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies. … [L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]

  10. Drug

    Lipoic acid

    go.drugbank.com/drugs/DB00166
    ApprovedInvestigationalNutraceutical

    A vitamin-like antioxidant.